Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

ProQR Therapeutics N.V. Ordinary Shares (PRQR)

https://www.proqr.com

ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

09/18/2014

Market Cap

182,923,328

Shares Outstanding

80,820,000

Weighted SO

81,157,493

Total Employees

N/A

Upcoming Earnings

08/01/2024

Similar Tickers

ANNX --.--%

ARWR --.--%

DAWN --.--%

TERN --.--%

ALNY --.--%

WVE --.--%

BPMC --.--%

APLS --.--%

ASMB --.--%

Beta

0.4180

Last Div

0.0000

Range

1.11-3.29

Chg

0.0100

Avg Vol

103540

Mkt Cap

182923328

Exch

NASDAQ

Country

NL

Phone

31 88 166 7000

DCF Diff

2.8543

DCF

-0.5943

Div Yield

0.0000

P/S

10.7969

EV Multiple

-3.8575

P/FV

5.0525

Div Yield %

0.0000

P/E

-7.7393

PEG

-0.5333

Payout

0.0000

Current Ratio

2.7298

Quick Ratio

2.7298

Cash Ratio

2.1184

DSO

107.9299

DIO

0.0003

Op Cycle

107.9301

DPO

8.5495

CCC

99.3806

Gross Margin

0.9084

Op Margin

-1.8503

Pretax Margin

-1.3915

Net Margin

-1.3951

Eff Tax Rate

0.0109

ROA

-0.1817

ROE

-0.5521

ROCE

-0.3522

NI/EBT

1.0026

EBT/EBIT

0.7520

EBIT/Rev

-1.8503

Debt Ratio

0.0387

D/E

0.1392

LT Debt/Cap

0.0000

Total Debt/Cap

0.1222

Int Coverage

0.0000

CF/Debt

-7.5120

Equity Multi

3.5932

Rec Turnover

3.3818

Pay Turnover

42.6925

Inv Turnover

999999.9999

FA Turnover

0.9440

Asset Turnover

0.1302

OCF/Share

-0.4210

FCF/Share

-0.4725

Cash/Share

1.1781

OCF/Sales

-2.2350

FCF/OCF

1.1223

CF Coverage

-7.5120

ST Coverage

-7.5120

CapEx Coverage

-8.1736

Div&CapEx Cov

-8.1736

P/BV

5.0525

P/B

5.0525

P/S

10.7969

P/E

-7.7393

P/FCF

-4.3043

P/OCF

-4.8311

P/CF

-4.8311

PEG

-0.5333

P/S

10.7969

EV Multiple

-3.8575

P/FV

5.0525

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Oct 25, 20:45 ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement GlobeNewswire Inc. Oct 23, 02:15 ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement GlobeNewswire Inc. Jan 19, 07:00 ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024 GlobeNewswire Inc. Dec 08, 07:30 ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets Benzinga Nov 08, 07:30 Bluebird Bio To Rally Around 267%? Here Are 10 Top Analyst Forecasts For Wednesday

Revenue Product Segmentation